Early KEYNOTE-013 reported 66 percent overall response (n=19/29) with 21 percent complete remission (n=6/29) and 89 percent of responses ongoing with median duration not yet reached in post-brentuximab vedotin transplant-failure and ineligible classical Hodgkin lymphoma, a signal that matured into 71.4 percent response with 16.6-month duration and 13.7-month progression-free survival at five years in KEYNOTE-087 and into randomized superiority in KEYNOTE-204 with median progression-free survival 13.2 months versus 8.3 months for brentuximab vedotin (hazard ratio 0.65). [1][2] Nivolumab as the direct anti-PD-1 peer showed 69 percent response in Checkmate 205 with no head-to-head data, while brentuximab vedotin as CD30-directed antibody-drug conjugate remains mechanistically distinct and serves only as active comparator. [3][4] Payer conversion required more than response: NICE moved from non-recommendation to routine recommendation in TA967 with 2-year stopping and confidential discount, G-BA granted hint of considerable additional benefit only where brentuximab vedotin is appropriate therapy, and CADTH conditioned reimbursement on price reductions of 13 percent to 29 percent against ICERs of $733,624 to $2,071,825 per QALY. [2] Regulatory positioning stays as monotherapy third-line or later with retreatment response 73.7 percent, but overall survival remains immature with final analysis planned for 2025, transplant-related graft-versus-host risk persists, and single-arm n=29 data cannot carry pivotal weight against Phase 3 RCT evidence. [5][6]
KEYNOTE-013 n=29 single-arm ORR 66% upgraded by KEYNOTE-204 Phase 3 PFS HR 0.65, yet OS immature and payer ICERs exceed thresholds. [2]
| Indication | Classical Hodgkin Lymphoma |
| Drug | Pembrolizumab |
| Mechanism of Action | PD-1 inhibitor |
| Company | Merck |
| Trial Phase | Phase 1b |
| Trial Acronym | KEYNOTE-013 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Hematology |
| Conference Name | 56th American Society of Hematology (ASH) Annual Meeting |
| Overall Response Rate (ORR) | 66 percent (n=19/29) |
| Complete Remission (CR) | 21 percent (n=6/29) |
| Patient Population | Transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma whose disease progressed on or after treatment with brentuximab vedotin |
| Prior Treatment | Brentuximab Vedotin |
| Dosage | 10 mg/kg every two weeks |
| Number of Patients | 29 |
| Median Duration of Response | Not yet reached (range 1+ to 185+ days) |
| Primary Endpoints (KEYNOTE-013) | Overall safety, tolerability, and complete remission rate |
| Planned Future Study | Phase 2 trial (KEYNOTE-087) in classical Hodgkin Lymphoma in the first half of 2015 |
Merck Presents Promising KEYTRUDA Data in Relapsed/Refractory cHL
Merck announced early findings from the ongoing Phase 1b KEYNOTE-013 study for KEYTRUDA (pembrolizumab) in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after brentuximab vedotin. Presented at the 56th American Society of Hematology (ASH) Annual Meeting, the study demonstrated an overall response rate (ORR) of 66 percent (n=19/29) and a complete remission (CR) rate of 21 percent (n=6/29). At the time of analysis, 89 percent of responses were ongoing, with the median duration of response not yet reached. These promising results support further investigation, with a Phase 2 trial (KEYNOTE-087) in cHL planned for the first half of 2015.
- The Phase 1b KEYNOTE-013 study showed significant anti-tumor activity for KEYTRUDA monotherapy in a challenging patient population of transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma. An overall response rate of 66% (19 out of 29 patients) was observed, with 21% achieving a complete remission (6 out of 29 patients), indicating substantial clinical benefit in patients who had progressed on prior brentuximab vedotin treatment.
- Early findings highlighted the durability of responses, with 89% (17 out of 19) of observed responses still ongoing at the time of analysis. The median duration of response had not yet been reached, with individual response durations ranging from 1+ to 185+ days. This suggests a sustained therapeutic effect for KEYTRUDA in this patient group, which is crucial for managing relapsed/refractory cancers.
- KEYTRUDA's safety profile in this cHL cohort was consistent with previously reported data, with no Grade 4 treatment-related adverse events or deaths. The most common adverse events were manageable. Based on these promising early results, Merck plans to initiate a Phase 2 trial (KEYNOTE-087) in classical Hodgkin Lymphoma in the first half of 2015, underscoring the potential of PD-1 pathway inhibition in blood cancers.
Addressing Unmet Needs in Relapsed/Refractory cHL
Recent literature on classical Hodgkin lymphoma (cHL) reflects high cure rates of up to 90% alongside persistent gaps in age-adapted efficacy, tolerability, and long-term toxicity. Key efforts over the past 3 years focus on tailoring frontline and salvage strategies to vulnerable age groups and refractory disease while reducing treatment burden through PET-adapted and novel-agent approaches.
Adolescents and young adults (age 15-39 years): HL represents one of the more common cancers in this group, yet age-related differences in biology, optimal frontline pediatric versus adult approaches, supportive care, and risks for long-term adverse effects remain understudied, driving recently completed and ongoing studies to harmonize risk group definition and trial eligibility criteria and advance holistic care.
Older fit versus frail patients, including those aged over 60 years and aged ≥61 years with comorbidities contraindicating standard chemotherapy: Poor outcomes due to age-related comorbidities and treatment-related toxicity require comprehensive geriatric assessment, pre-phase corticosteroids, growth factor prophylaxis, and organ function monitoring, with Nivolumab plus doxorubicin, vinblastine, and dacarbazine (Nivo + AVD) emerging for fit older patients and chemo-free approaches with brentuximab vedotin (BV) and checkpoint inhibitors, including nivolumab with or without vinblastine, as alternatives for frail patients unfit for classical chemotherapy.
Primary refractory and relapsed disease, including failure after high-dose chemotherapy and autologous stem cell transplantation (auto-SCT): Outcomes remain poorer than for relapsed HL, with adverse factors including stage III-IV at relapse, mediastinal involvement, and absence of complete remission after salvage chemotherapy, supporting prognostic stratification, PET/CT-directed response-adapted treatment, integration of BV and anti-PD1 checkpoint inhibitors into salvage regimens prior to ASCT or as post-transplant maintenance, and investigation of anti-CD30 CAR-T cells and the anti-CD30/CD16A bispecific antibody AFM13 with preactivated allogeneic cord blood-derived NK cells for patients who have failed approved options.
Reduction of acute and late treatment toxicities while maintaining efficacy: Interim fluorodeoxyglucose (FDG)-PET after 2 cycles guides escalation/de-escalation, including omitting bleomycin in PET2-negative patients and early intensification in PET2-positive patients as evidenced by RATHL, AHL2011, HD18, SWOG S0816 and HD0607, to minimize infertility, cardiovascular complications, secondary primary malignancies including non-Hodgkin lymphomas, breast, lung, and colorectal cancers and myelodysplasia, cardiopulmonary and thyroid dysfunction, and gonadal toxicity where sperm cryopreservation remains the gold standard for young males.
KEYNOTE-013: Promising Early Data for Pembrolizumab in cHL
A recent phase 3 clinical trial (S1826, NCT03907488) compared brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) with nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD) in classical Hodgkin lymphoma (cHL). At a median follow-up of 1-year, N-AVD improved PFS vs BV-AVD and few immune adverse events were observed. In a pre-planned subset analyses of cHL patients ages ≥60 years, the 1-year PFS for N-AVD was 93% (95% CI, 79%-98%) versus 64% (95% CI, 45%-77%) for BV-AVD, and N-AVD was largely better tolerated particularly in older patients, which included markedly less neuropathy, lower treatment discontinuation, and less nonrelapse mortality.
In newly diagnosed cHL, a multicenter, single-arm, phase 2 investigator-initiated trial (NCT03226249) evaluated sequential pembrolizumab and doxorubicin, vinblastine, and dacarbazine (AVD) chemotherapy in 30 patients with early, unfavorable, or advanced-stage disease. Patients received 3 cycles of pembrolizumab monotherapy followed by AVD for 4 to 6 cycles; after pembrolizumab monotherapy, 11 patients (37%) demonstrated CMRs, and an additional 7 of 28 (25%) patients with quantifiable positron emission tomography computed tomography scans had >90% reduction in metabolic tumor volume, while all patients achieved CMR after 2 cycles of AVD and maintained their responses at the end of treatment with a median follow-up of 22.5 months (range, 14.2-30.6) with no changes in therapy, progressions, or deaths. Therapy was well tolerated, with the most common immune-related adverse events being grade 1 rash (n = 6) and grade 2 infusion reactions (n = 4), plus one reversible grade 4 transaminitis and one reversible Bell's palsy. In high-risk advanced-stage disease, the ECHELON-1 study compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) after a median follow-up of 37.1 months, showing PFS at 3 years as assessed by investigator in Stage IV disease (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032) and in IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012), with the most common adverse events in A + AVD-treated versus ABVD-treated patients with Stage IV disease of peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%).
In relapsed or refractory cHL, the phase 2 KEYNOTE-087 (NCT02453594) trial evaluated pembrolizumab monotherapy for ≤2 years in patients with progressive disease after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), salvage chemotherapy and BV without ASCT, or ASCT without subsequent BV. With median follow-up of 63.7 months, ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%), median duration of response (DOR) was 16.6 months and median progression-free survival was 13.7 months, with a quarter of responders including half of complete responders maintaining response for ≥4 years and median overall survival not achieved. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients, with no treatment-related deaths occurring.
Pembrolizumab's Broad Potential Beyond Hodgkin Lymphoma
Pembrolizumab is being evaluated across multiple solid tumors and hematologic malignancies beyond classical Hodgkin lymphoma. The retrieved literature describes phase 1 to phase 3 programs using single-arm, randomized open-label, double-blind, and maintenance designs in both early-stage and metastatic settings.
Non-small cell lung cancer (NSCLC): open-label, single-center, single-arm phase 2 trial of adjuvant pembrolizumab for up to two years after complete resection following neoadjuvant concurrent chemoradiation therapy in stage IIIA/N2 disease; multicentre, single-arm, open-label, phase 2 PePS2 trial of pembrolizumab 200 mg every 3 weeks in performance status 2 patients; open-label, randomized controlled phase 3 KEYNOTE-024 of pembrolizumab 200 mg once every 3 weeks for up to 35 cycles versus platinum-based chemotherapy in previously untreated metastatic disease with PD-L1 tumor proportion score of at least 50%; phase 3 open-label 3475A-D77 study of pembrolizumab SC 790 mg every 6 weeks versus pembrolizumab IV 400 mg every 6 weeks, each given with platinum doublet chemotherapy, in newly diagnosed stage IV disease; prospective pilot study of 2 cycles of pembrolizumab 2 mg/kg with chemotherapy via intravenous administration every 3 weeks followed by surgical treatment 3-4 weeks after the second cycle in stage IIB-IIIB resectable lung squamous cell carcinoma; phase 3 KEYLYNK-006 trial randomized 1:1 to olaparib 300 mg orally twice daily or pemetrexed every three weeks, both given with up to 31 cycles of pembrolizumab every three weeks, as maintenance after induction with pembrolizumab 200 mg every three weeks plus pemetrexed and carboplatin or cisplatin; randomized, double-blind, phase 3 ZEAL-1L study of niraparib-plus-pembrolizumab versus placebo-plus-pembrolizumab as maintenance therapy with intravenous pembrolizumab at 200 mg every 3 weeks.
Melanoma: multicentre, open-label, randomised, phase 3 KEYNOTE-006 trial randomly assigned 1:1:1 to intravenous pembrolizumab every 2 weeks, intravenous pembrolizumab every 3 weeks, or intravenous ipilimumab every 3 weeks for four doses in unresectable stage III or IV disease.
Triple-negative breast cancer (TNBC): phase 3 KEYNOTE-522 study randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo every 3 weeks plus chemotherapy for 8 cycles followed by surgery and adjuvant pembrolizumab or placebo for up to 9 cycles in high-risk early-stage disease; open-label phase 2 NeoPACT trial of single-group carboplatin and docetaxel plus pembrolizumab 200 mg every 21 days for 6 cycles in stage I to III disease.
Gynecologic and genitourinary cancers: open-label, non-comparative, 2:1 randomized, phase II NeoPembrOV trial of pembrolizumab 200 mg every 3 weeks added to carboplatin plus paclitaxel with postoperative continuation for a maximum of 2 years in stage IIIC/IV high-grade serous carcinoma; phase 3, randomized 1:1, open-label, active-controlled ENGOT-en9/LEAP-001 trial of pembrolizumab intravenously every 3 weeks plus lenvatinib orally daily versus paclitaxel plus carboplatin intravenously every 3 weeks in newly diagnosed stage III/IV or recurrent endometrial cancer; phase 3, randomized, double-blind LEAP-011 trial randomized 1:1 to pembrolizumab 200 mg intravenously every 3 weeks plus lenvatinib 20 mg or placebo orally once daily as first-line therapy for advanced urothelial carcinoma; randomized double-blind phase II study of switch maintenance pembrolizumab 200 mg intravenously once every 3 weeks versus placebo for up to 24 months after first-line platinum-based chemotherapy in metastatic urothelial cancer.
Gastrointestinal, neuroendocrine, prostate, rectal and other solid tumors: randomized, multiregional KEYNOTE-811 trial comparing pembrolizumab plus trastuzumab and chemotherapy versus placebo plus trastuzumab and chemotherapy for unresectable or metastatic HER2-positive gastric or gastroesophageal junction carcinoma; open-label, phase 2, randomized 1:1 NRG-GI002 trial of neoadjuvant FOLFOX for 4 months then chemoradiotherapy with or without intravenous pembrolizumab 200 mg every 3 weeks for up to 6 doses before surgery in stage II/III locally advanced rectal cancer; two open-label, phase 2 studies of pembrolizumab at 200 mg intravenously every 3 weeks in previously treated metastatic high-grade neuroendocrine neoplasms; phase 1b/2 KEYNOTE-365 cohort C of pembrolizumab 200 mg intravenously every 3 weeks plus enzalutamide 160 mg orally once daily in abiraterone acetate-pretreated metastatic castration-resistant prostate cancer; single-arm phase Ib trial of T-DM1 3.6 mg/kg every 21 days plus pembrolizumab 200 mg every 21 days in metastatic HER2-positive breast cancer; phase I 3+3 design of mogamulizumab with pembrolizumab 200 mg on day 1 of each 21-day cycle in relapsed or refractory non-Hodgkin lymphoma.
Frequently Asked Questions
References
- [1] Mehdizadeh M, Tehrani HA et al.. Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation. Blood cell therapy. 2023 Aug 25. 38146357
- [2] Pedersen ESL, Fischer H et al.. Adolescents and young adults with cancer in Switzerland: a large retrospective single-centre cohort analysis of key care pathways and outcomes by sex and age. Swiss medical weekly. 2026 Aug 31. 42781746
- [3] Middleton G, Brock K et al.. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet. Respiratory medicine. 2020 Sep. 32199466
- [4] Omar MN, Elsayed ZM et al.. A Prospective Study Comparing Treatment Outcomes of Brentuximab Vedotin Plus AVD versus ABVD in Egyptian Patients with Advanced Classical Hodgkin Lymphoma. The Gulf journal of oncology. 2026 Jan. 42274064
- [5] Rahma OE, Yothers G et al.. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA oncology. 2021 Aug 1. 34196693
- [6] Latif K, Courtad I et al.. Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis. Hematology reports. 2026 Jul 31. 42645792
- [7] Cohen YI, Lebel E et al.. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation. Transplantation and cellular therapy. 2023 Aug. 37160229
- [8] Geantă M, Cioroboiu C. The FDA Changed Everything. Biomedicine hub. 2017 Nov-Dec. 31988934
- [9] Simsek M, Tekin SB et al.. Immunological Agents Used in Cancer Treatment. The Eurasian journal of medicine. 2019 Feb. 30911265
- [10] Casak SJ, Zhang Y et al.. FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026 May 15. 41790455
- [11] Rusconi C, Barone A et al.. Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD. Leukemia & lymphoma. 2025 May. 39797589
- [12] Xu K, Yu M et al.. Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis. Annals of medicine. 2025 Dec. 40131366
- [13] Lazarovici J, Amorim S et al.. Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study. Haematologica. 2026 May 28. 42206423
- [14] Prusak M, Brylka K et al.. Male infertility as a late side effect of oncological treatment of Hodgkin lymphoma in childhood and adolescents and the possible prevention. Frontiers in oncology. 2025. 41220951
- [15] Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clinical therapeutics. 2009. 20110042
- [16] Kelly KM, Friedberg JW. Classic Hodgkin Lymphoma in Adolescents and Young Adults. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Feb 20. 37983570
- [17] Salihoglu A, Elverdi T et al.. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Annals of hematology. 2015 Mar. 25231929
- [18] Lorente Fernández L, Romero Domínguez S et al.. [Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2025 Jan-Feb. 39424522
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com










